Table 4 Outcome of patients with KRAS or BRAF mutations stratified according to EGFR FISH status
From: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Total | Response rate ( N/%) | Time to progression (months) | Survival (months) | |
|---|---|---|---|---|
EGFR FISH+/KRAS+ | 22 | 4/18.2 | 5.3 | 13.8 |
EGFR FISH+/KRAS− | 19 | 9/47.4 | 7.4 | 9.8 |
P-value | 0.04 | 0.2 | 0.3 | |
EGFR FISH−/KRAS+ | 20 | 0 | 3.5 | 7.8 |
EGFR FISH−/KRAS− | 19 | 1/5.3 | 3.2 | 10.8 |
P-value | 0.4 | 1.0 | 0.5 | |
EGFR FISH+/KRAS+ or BRAF+ | 24 | 4/16.7 | 5.4 | 9.5 |
EGFR FISH+/KRAS− and BRAF− | 16 | 8/50.0 | 7.8 | 17.9 |
P-value | 0.03 | 0.1 | 0.1 | |
EGFR FISH−/KRAS+ or BRAF+ | 22 | 0 | 3.4 | 7.8 |
EGFR FISH−/KRAS− and BRAF− | 17 | 1/5.9 | 3.8 | 10.8 |
P-value | 0.4 | 0.5 | 0.5 |
